Alimera Completes Recruitment for Its NEW DAY Study Evaluating Iluvien for DME

Alimera Sciences announced that it has completed enrollment for the company’s NEW DAY clinical trial, a randomized, controlled, multicenter study designed to generate prospective data for Iluvien (fluocinolone acetonide intravitreal implant, 0.19mg) as a baseline therapy in patients diagnosed with diabetic macular edema (DME).

“We believe that this study is the largest head-to-head comparison of any corticosteroid therapy and anti-VEGF therapy in the treatment of newly diagnosed patients suffering from DME. From this study, we look forward to sharing data in early 2025, which we expect will support a change to the current paradigm of DME treatment, offering patients a first-line treatment option that can maintain vision longer with fewer injections than other therapies,” said Rick Eiswirth, Alimera’s president and CEO. “We continue to have great confidence in this study as our most recent PALADIN data further indicated that the benefits of Iluvien are realized earlier when used early in DME treatment. We would like to thank all the investigators, staff, and patients who are participating in our NEW DAY study.”